Market revenue in 2023 | USD 10.2 million |
Market revenue in 2030 | USD 37.6 million |
Growth rate | 20.5% (CAGR from 2023 to 2030) |
Largest segment | Cell & gene therapy |
Fastest growing segment | Cell & Gene Therapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cell & Gene Therapy, Immunotherapy |
Key market players worldwide | Charles River Laboratories International Inc, Boehringer Ingelheim, Thermo Fisher Scientific Inc, Lonza Group Ltd, Viva Biotech, VGXI, PlasmidFactory, BioCina, TriLink BioTechnologies, Esco Aster |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to plasmid dna contract manufacturing market will help companies and investors design strategic landscapes.
Cell & gene therapy was the largest segment with a revenue share of 59.8% in 2023. Horizon Databook has segmented the India plasmid dna contract manufacturing market based on cell & gene therapy, immunotherapy covering the revenue growth of each sub-segment from 2018 to 2030.
The prevalence of chronic diseases is increasing in the country and pDNA has a wide application in the industry, which are the primary factors contributing to growth of the market. Furthermore, the wide use of pDNA in manufacturing the vaccines, especially in COVID-19 vaccines, increases the demand for the pDNA contract manufacturing market.
For instance, India approved the first COVID-19 DNA vaccine in September 2021. It is the first COVID-19 DNA vaccine ever created and was produced as a result of Mission COVID Suraksha in collaboration with DBT-BIRAC. India's ZyCoV-D immunization uses circular DNA to protect against COVID-19 infection.
The Indian government approved Zydus Cadila's DNA vaccine under emergency use authorization, citing results from phase III clinical studies that showed a roughly 66.0% efficacy for symptomatic cases. Thus, the wide use of the pDNA in vaccines & therapies is expected to drive the demand of the pDNA contract manufacturing market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the India plasmid dna contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into India plasmid dna contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account